ClinicalTrials.gg
CompletedNCT05345769Updated Dec 12, 2024

Safety and Efficacy of AM712 in Patients with NAMD

A Phase 1 interventional study of AM712(ASKG712) in Neovascular Age-related Macular Degeneration, sponsored by AffaMed Therapeutics Limited. Completed at 9 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.

Sponsored by AffaMed Therapeutics Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
369th of 491
21 · median 55
Started
2022
with 35 others
Phase 1
91 of 645
10 open now
Registered
510th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 369th largest by enrollment of the 491 interventional ones that give a count, is one of 36 that started in 2022, is one of 91 in phase 1, and was the 510th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in patients with neovascular age- related macular degeneration (nAMD).

Read the detailed description

The Part 1 of study is a multicenter, open-label, sequentially, multiple ascending-dose study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in subjects with nAMD.

Subjects will be sequentially enrolled into different dose-level cohorts following the traditional "3+3" design until the maximally tolerated dose (MTD) or the maximally administered dose (MAD) has been reached.

The Part 2 of study is a multicenter, open-label, sequential study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in treatment-naïve patients with nAMD.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration

Keywords

  • nAMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects with 50 years of age or older
  2. Active sub-foveal CNV lesion secondary to nAMD including juxta or extra-foveal lesions that partially affect the fovea
  3. The area of CNV must occupy at least 50% of total lesion
  4. Total lesion area ≤ 12 DA
  5. ETDRS BCVA letter score measured at screening and baseline
  6. Clear ocular media and adequate pupil dilation to permit good quality photographic imaging in study eye

Exclusion criteria

Exclusion Criteria:

  1. Any previous systemic anti-VEGF treatment
  2. Any systemic treatment or therapy to treat neovascular AMD
  3. Continuous use of systemic
  4. Diseases that affect intravenous injection and venous blood sampling
  5. Presence of CNV due to other causes, such as ocular histoplasmosis, trauma, multifocal choroiditis, angioid streaks, history of choroidal rupture, or pathologic myopia in study eye
  6. History or any concurrent ocular condition which, in opinion of investigator, could either confound interpretation of efficacy and safety of IP or require medical or surgical intervention.
  7. The area of fibrosis occupies ≥ 50% of total lesion area in study eye
  8. Evidence of myopia degeneration, diagnosis supported by the axial length examination in study eye
  9. History or any concurrent macular abnormality other than AMD in study eye
  10. Current vitreous hemorrhage or history of vitreous hemorrhage in study eye
  11. History of recurrent inflammation in study eye
  12. History of treatment for nAMD
  13. Subject having out of range laboratory values defined as:

or AST > 2 x , total > 1.5 x ULN Serum creatinine > 1.5 x ULN, BUN > 2 x ULN > 7.5% at screening

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Phase I- All

    Subjects with neovascular AMD

    Biological: AM712(ASKG712)

Interventions

  • BiologicalAM712(ASKG712)

    AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.

06

What researchers measure

Primary outcomes

  1. Incidence of ocular adverse events (AEs) of the study eyes

    To evaluate the safety and tolerability of AM712 in Subjects with neovascular Age-related Macular Degeneration (nAMD)

    Time frame: 252 days

  2. Incidence of non-ocular AEs

    To evaluate the safety and tolerability of AM712 in Subjects with neovascular Age-related Macular Degeneration (nAMD)

    Time frame: 252 days

  3. Any relevant safety observations derived from BCVA

    To evaluate the safety and tolerability of AM712 in Subjects with neovascular Age-related Macular Degeneration (nAMD)

    Time frame: 252 days

  4. Any relevant safety observations derived from SD-OCT

    To evaluate the safety and tolerability of AM712 in Subjects with neovascular Age-related Macular Degeneration (nAMD)

    Time frame: 252 days

Secondary outcomes

  1. Mean change from baseline in central subfield thickness as assessed by SD-OCT

    To evaluate the efficacy of AM712 in Subjects with nAMD

    Time frame: 252 days

  2. Proportion of patients with no intraretinal fluid, subretinal fluid, or pigment epithelial detachment as assessed by SD-OCT

    To evaluate the efficacy of AM712 in Subjects with nAMD

    Time frame: 252 days

  3. Mean change from baseline in BCVA (ETDRS)

    To evaluate the efficacy of AM712 in Subjects with nAMD

    Time frame: 252 days

  4. Proportion of patients gaining ≥ 15 letters from baseline BCVA

    To evaluate the efficacy of AM712 in Subjects with nAMD

    Time frame: 252 days

07

Study locations

9 sites
  • Retina Consultants San Diego
    Poway, California 92064, United States
  • Bay Area Retina Associates
    Walnut Creek, California 94598, United States
  • Colorado Retina
    Lakewood, Colorado 80228, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Retina Research Institute at New England Retina Consultants
    Springfield, Massachusetts 01107, United States
  • Tennessee Retina, PC
    Nashville, Tennessee 37203, United States
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Retina Consultants of Texas
    San Antonio, Texas 78240, United States
  • Retina Consultants of Texas
    The Woodlands, Texas 77384, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Nov 2024, 30 months.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 30 months is above that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
Apr 26, 2022
StartActual
Apr 28, 2022
Primary completionActual
Nov 4, 2024
CompletionActual
Nov 4, 2024
Last update
Dec 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05345769
Lead sponsor
AffaMed Therapeutics Limited
Responsible party
Sponsor
First posted
Apr 26, 2022
Start date
Apr 28, 2022
Primary completion
Nov 4, 2024
Completion
Nov 4, 2024
Last update
Dec 12, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion